瘤内溶瘤病毒治疗联合立体定向体部放疗后序贯帕博利珠单抗治疗转移性非小细胞肺癌的2期研究
STOMP是一项单臂开放标签2期研究,入组28例转移性非小细胞肺癌患者,接受瘤内注射ADV/HSV-tk(5×10^11 vp)联合SBRT(30 Gy/5次),后序贯帕博利珠单抗200 mg静脉每3周一次直至疾病进展或不可耐受毒性。27例可评估疗效者客观缓解率为33.3%,临床获益率70.4%,全组中位无进展生存期7.4个月,中位总生存期18.1个月,3级及以上毒性发生率为21.4%。
要点
- 27例可评估患者客观缓解率33.3%(完全缓解2例,部分缓解7例),临床获益率70.4%。
- 全组中位无进展生存期7.4个月(95%CI 5.1-9.6个月),中位总生存期18.1个月(95%CI 15.4-20.9个月)。
- 3级及以上毒性发生于6例(21.4%)患者,联合方案耐受性良好。
核心结论
- 瘤内ADV/HSV-tk联合伐昔洛韦基因治疗与SBRT作为免化疗策略增强帕博利珠单抗抗肿瘤效应,在转移性非小细胞肺癌患者中耐受性良好且令人鼓舞。
研究设计与样本
- STOMP为单臂、开放标签2期研究,入组转移性非小细胞肺癌患者28例,其中27例可评估疗效。
- 患者接受瘤内注射ADV/HSV-tk(5×10^11 vp)联合SBRT(30 Gy分5次),后序贯帕博利珠单抗200 mg静脉每3周一次直至疾病进展或不可耐受毒性。
- 主要终点为客观缓解率(完全缓解和部分缓解),次要终点包括临床获益率(完全缓解、部分缓解和疾病稳定)、无进展生存期、总生存期和安全性。
主要发现
- 客观缓解率为33.3%,包括完全缓解2例(7.4%)和部分缓解7例(25.9%)。
- 临床获益率为70.4%。
- 8例免疫检查点抑制剂难治患者中6例(75.0%)获得临床获益。
- 缓解者疗效持久,中位无进展生存期和总生存期未达到。
- 全组中位无进展生存期为7.4个月(95%CI 5.1-9.6个月),中位总生存期为18.1个月(95%CI 15.4-20.9个月)。
关键数值与推荐
- 瘤内注射ADV/HSV-tk剂量为5×10^11 vp。
- SBRT剂量为30 Gy分5次。
- 帕博利珠单抗剂量为200 mg静脉每3周一次,直至疾病进展或不可耐受毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A phase 2 study of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy in metastatic non-small cell lung cancer (mNSCLC) followed by pembrolizumab (STOMP) was designed to explore the dual approach in enhancing single pembrolizumab with ADV/HSV-tk plus valacyclovir gene therapy and SBRT in mNSCLC. METHODS AND MATERIALS: STOMP is a single-arm, open-label phase 2 study. Patients with mNSCLC received intratumoral injections of ADV/HSV-tk (5 × 1011 vp) and SBRT (30 Gy in 5 fractions) followed by pembrolizumab 200 mg IV every 3 weeks until disease progression or intolerable toxicity. The primary endpoint was overall response rate (ORR) (complete response [CR] and partial response [PR]). Secondary endpoints included clinical benefit rate (CBR) (CR, PR and stable disease [SD]), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: 28 patients were enrolled, of whom 27 were evaluated for response. The ORR was 33.3%, including 2 CR (7.4%) and 7 PR (25.9%). CBR was 70.4%. Six of eight (75.0%) patients who were immune checkpoint inhibitor (ICI) refractory derived clinical benefits. Responders had durable responses with median PFS, and OS not reached. The entire cohort had a median PFS of 7.4 months (95% CI, 5.1-9.6 months), and median OS of 18.1 months (95% CI, 15.4-20.9 months). The combination was well tolerated, with grade 3 or higher toxicity in 6 (21.4%) patients. CONCLUSIONS: The dual approach of in situ ADV/HSV-tk plus valacyclovir gene therapy and SBRT as a chemotherapy-sparing strategy to enhance the antitumor effect of pembrolizumab is a well-tolerated encouraging treatment in patients with mNSCLC.
引用
- Guan J, Sun K, Guerrero CA, et al. A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37625523. doi:10.1016/j.ijrobp.2023.08.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。